<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/81B6349F-114E-4934-8047-4F3D541C5A60"><gtr:id>81B6349F-114E-4934-8047-4F3D541C5A60</gtr:id><gtr:name>Amylin Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/81B6349F-114E-4934-8047-4F3D541C5A60"><gtr:id>81B6349F-114E-4934-8047-4F3D541C5A60</gtr:id><gtr:name>Amylin Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/69B28B24-560A-483F-9FC8-3D8C9D7DCAFD"><gtr:id>69B28B24-560A-483F-9FC8-3D8C9D7DCAFD</gtr:id><gtr:firstName>V Krishna K</gtr:firstName><gtr:surname>Chatterjee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5E276E4B-FE32-4343-8604-D30D82621A8A"><gtr:id>5E276E4B-FE32-4343-8604-D30D82621A8A</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Finer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/60F94A2A-4B83-4F9C-8F07-A4260DCE0450"><gtr:id>60F94A2A-4B83-4F9C-8F07-A4260DCE0450</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>O'Rahilly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/63FEB49D-D5E7-4269-85A9-D059AEE1E0F5"><gtr:id>63FEB49D-D5E7-4269-85A9-D059AEE1E0F5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Bousfield</gtr:otherNames><gtr:surname>Savage</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5FB1E0BA-FEB5-48CA-A750-72009C384555"><gtr:id>5FB1E0BA-FEB5-48CA-A750-72009C384555</gtr:id><gtr:firstName>Sadaf</gtr:firstName><gtr:surname>Farooqi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0502115"><gtr:id>6EAC4FA7-B4B7-4B7B-BEE6-D8F742335C22</gtr:id><gtr:title>Targeting therapy to molecular mechanism of disease in obesity and related metabolic disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502115</gtr:grantReference><gtr:abstractText>Obesity and its complications such as diabetes are major and growing public health problems. We have been investigating genetic factors involved in human obesity and a condition called insulin resistance which leads to diabetes, by focusing on patients with severe forms of these diseases from an early age. We have found defects in several genes that cause these diseases. In one disease, called congenital leptin deficiency, we have been able to show the dramatically beneficial effects of leptin therapy. We now want to study the effects of different diets and drug treatments including leptin in additional patient groups. Defining treatment responses in patients with a known genetic condition that effects a key system in the body will help us to understand and treat these patients but also guide our approach to the more common forms of these important diseases.</gtr:abstractText><gtr:technicalSummary>Despite the fact that obesity and type 2 diabetes are among the most common chronic diseases, the range of therapeutic options available for the treatment of these disorders is very limited and the therapeutic responses to such interventions are highly variable. This is likely to reflect, at least in part, the underlying heterogeneity of these disorders with multiple pathophysiological routes leading to the end points of increased adipose mass or hyperglycaemia respectively. Over the past decade or more we have been attempting to unravel the aetiological complexity of these disorders. By focusing on subjects with extreme phenotypes of obesity or insulin resistance we have discovered several previously unknown monogenic/digenic disorders leading to these conditions. These include disorders of the leptin-melanocortin signalling pathways leading to obesity and defects in insulin signalling molecules and PPARgamma leading to extreme insulin resistance. 

We now propose to undertake interventional studies in patients with genetically defined syndromes of severe obesity and insulin resistance. These will allow the efficacy of commonly used interventions to be tested in patients with a specific defect in a particular physiological pathway. We will perform a range of detailed metabolic measurements in well-defined subgroups of patients and controls before and in response to dietary and pharmacological manipulations. These mechanistic studies in humans will provide novel information about the requirement for the intactness of specific pathways in the mediation of a therapeutic effect. These interventions will provide novel information about the mechanism of drug action in humans and may pave the way for better targeting of therapy in commoner forms of diabetes and obesity.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>588764</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amylin Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>amylin corp</gtr:description><gtr:id>891CB70F-32F5-438F-8928-CBFB0B8F2371</gtr:id><gtr:impact>clinical benefits for patients. to be reported</gtr:impact><gtr:partnerContribution>provision of recombinant leptin for human use</gtr:partnerContribution><gtr:piContribution>identification of suitable patients</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>SOR SAC Crick Institute</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE14F951-A51A-4691-8701-581438182F73</gtr:id><gtr:impact>Scientific Advisory Board

None</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR BBC TV and Radio Interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B35E26C3-F625-49D8-946F-5A9F0B3CA11F</gtr:id><gtr:impact>Raise awareness of research and IMS to the public

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR Lancet article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>38542BEA-4DF4-4D7A-ACE8-BDAD64850185</gtr:id><gtr:impact>Raised awareness of research and IMS

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://download.thelancet.com/pdfs/journals/lancet/PIIS0140673613616220.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR RTE interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F8CF4DA7-79DF-4D13-982A-24DD16AB2B7A</gtr:id><gtr:impact>Raised awareness of research and IMS to the public

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR SAC Conway</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C35D7276-D721-4A9E-9CAC-5D428FBE389B</gtr:id><gtr:impact>Scientific Advisory Board

None</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR SAC Fondation Leducq</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2640775D-B5E6-4D70-B07D-305B50A594CA</gtr:id><gtr:impact>Scientific Advisory Committee

None</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR MRC Centenary Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6B1CB1AA-FDE3-4D0B-9CBF-EE500C3AA0EC</gtr:id><gtr:impact>Raised awareness of research and IMS among public

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR JCI Interview-Conversations with Giants in Medicine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>984125BF-FA9A-4542-9A56-F4F2E7DE3575</gtr:id><gtr:impact>Raised awareness of research and IMS

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.jci.org/videos/cgms</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR Research Lecture Karolinska Institute, Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B892FA46-DB31-4CF1-88EF-77953C84D0B2</gtr:id><gtr:impact>Raised awareness of research and IMS among peers

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR CSaP</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>35288DAB-C3C0-4DAA-B7A1-23E3A1F9D0A0</gtr:id><gtr:impact>Member of Centre for Science &amp;amp; Policy Executive Committee, University of Cambridge

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetic causes of obesity</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B732A7A7-E3EC-42E8-AFBF-460C0529DE26</gtr:id><gtr:impact>Berzelius symposium, Umea

improved knowledge of health professionals regarding advances in obesity</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Human obesity &amp; insulin resistance: lessons from the extremes</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8DDAD9D2-0F53-481B-BC2D-9CFF79D77790</gtr:id><gtr:impact>presentation as the Wilkins Visiting Professor for Evan Days

improved knowledge of health professionals regarding advances in obesity</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR Academy of Medical Sciences</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9F8120E1-61BB-4700-9F8B-58D473638C44</gtr:id><gtr:impact>Raised awareness of research and IMS

None</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR Naked Scientist Question of the Week</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>500A5988-04B6-49E6-BFE5-DC4890BD9547</gtr:id><gtr:impact>Raised awareness of research and IMS to public

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/podcasts/qotw/show/20130307/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR, Galway Diabetes Research Centre</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C260F044-B80C-4CD7-B678-49F9A4E0106B</gtr:id><gtr:impact>http://www.conference.ie/Conferences/menu.asp?menu=1088&amp;amp;Conference=190

raised awareness of research are and IMS among peers</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SOR Irish Medical News feature</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>89489409-FCC2-4FCC-BCF4-44467ED9EC24</gtr:id><gtr:impact>Raised awareness of research and IMS

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.imn.ie/index.php?option=com_content&amp;view=article&amp;id=5418:arise-sir-orahilly&amp;catid=57:clinical-news&amp;Itemid=3</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>6493079</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Biomedical Research Centre</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>558C84FD-D33D-4019-A676-919A2B059B61</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50A128D0-540F-4795-BEA3-3013D86739B7"><gtr:id>50A128D0-540F-4795-BEA3-3013D86739B7</gtr:id><gtr:title>Leptin therapy in lipodystrophy.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb1e01bfe22783990512a06ab37abb1c"><gtr:id>bb1e01bfe22783990512a06ab37abb1c</gtr:id><gtr:otherNames>Savage DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E48C9CC5-A3DC-4976-A2DB-C9BA91B53707"><gtr:id>E48C9CC5-A3DC-4976-A2DB-C9BA91B53707</gtr:id><gtr:title>Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine.</gtr:title><gtr:parentPublicationTitle>Journal of obesity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/369a7b3b1cfaf21e69bc0b37d13ae9d6"><gtr:id>369a7b3b1cfaf21e69bc0b37d13ae9d6</gtr:id><gtr:otherNames>Napolitano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-0708</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C51574BF-97BB-4264-B701-666110D180D7"><gtr:id>C51574BF-97BB-4264-B701-666110D180D7</gtr:id><gtr:title>Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85c6bb34a4e6d89b4a4b3ac619523d87"><gtr:id>85c6bb34a4e6d89b4a4b3ac619523d87</gtr:id><gtr:otherNames>Regan FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3A7E390-A5C5-49D3-A8FF-7D87E9BA24F8"><gtr:id>F3A7E390-A5C5-49D3-A8FF-7D87E9BA24F8</gtr:id><gtr:title>An activating mutation of AKT2 and human hypoglycemia.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea1cb54c2e2cfa0bee51e680fe1e2dcf"><gtr:id>ea1cb54c2e2cfa0bee51e680fe1e2dcf</gtr:id><gtr:otherNames>Hussain K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C088990-8275-4FB4-9DB9-B4A3307B694E"><gtr:id>3C088990-8275-4FB4-9DB9-B4A3307B694E</gtr:id><gtr:title>Distinct modulatory effects of satiety and sibutramine on brain responses to food images in humans: a double dissociation across hypothalamus, amygdala, and ventral striatum.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5199f9b15d112036e6d266d0a3dbea9b"><gtr:id>5199f9b15d112036e6d266d0a3dbea9b</gtr:id><gtr:otherNames>Fletcher PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6B7F86A-BF55-4908-A09B-385F7FB6404D"><gtr:id>C6B7F86A-BF55-4908-A09B-385F7FB6404D</gtr:id><gtr:title>Complement abnormalities in acquired lipodystrophy revisited.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bb1e01bfe22783990512a06ab37abb1c"><gtr:id>bb1e01bfe22783990512a06ab37abb1c</gtr:id><gtr:otherNames>Savage DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19AA7B4D-CF65-4A5F-A813-924BCE3DEBC6"><gtr:id>19AA7B4D-CF65-4A5F-A813-924BCE3DEBC6</gtr:id><gtr:title>Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a92a770c3afb9f08de4d09f99c534177"><gtr:id>a92a770c3afb9f08de4d09f99c534177</gtr:id><gtr:otherNames>Farooqi IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88F30BE3-B8A0-43A9-AEA4-9F50B0C39162"><gtr:id>88F30BE3-B8A0-43A9-AEA4-9F50B0C39162</gtr:id><gtr:title>Fatty acid metabolism in patients with PPARgamma mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f4ccc7a03cfbcaeed5c2e7a5a2176d2a"><gtr:id>f4ccc7a03cfbcaeed5c2e7a5a2176d2a</gtr:id><gtr:otherNames>Tan GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56C8BE22-D1ED-4BEF-B07C-26766F8A42D0"><gtr:id>56C8BE22-D1ED-4BEF-B07C-26766F8A42D0</gtr:id><gtr:title>Lipodystrophy: metabolic insights from a rare disorder.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/120893d6db842ae2fac96265727b0fb4"><gtr:id>120893d6db842ae2fac96265727b0fb4</gtr:id><gtr:otherNames>Huang-Doran I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2721059D-9065-49DF-BB69-F59960FAED06"><gtr:id>2721059D-9065-49DF-BB69-F59960FAED06</gtr:id><gtr:title>Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/680a48ecbe7717257217c97eb2cbd187"><gtr:id>680a48ecbe7717257217c97eb2cbd187</gtr:id><gtr:otherNames>Semple RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/05953353-D660-404C-AFD2-FB6AC9C4BFCC"><gtr:id>05953353-D660-404C-AFD2-FB6AC9C4BFCC</gtr:id><gtr:title>KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04805c136fdc80831b34653a2466319a"><gtr:id>04805c136fdc80831b34653a2466319a</gtr:id><gtr:otherNames>Pearce LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502115</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>74DC189C-F240-42D1-84DD-85475A95ABE8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.7  Physical</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>